03 November 1997
Effects of high volume continous veno-venous hemofiltration in cardiac surgery patients with renal failure
Romuald Lango, Jan Rogowski, Janusz Siebert, Chris P. Stoutenbeek, Heleen M. Oudemans-van Straaten, Durk F. ZandstraMed Sci Monit 1997; 3(6): CR813-820 :: ID: 501786
Abstract
Acute Renal Failure following cardio-pulmonary bypass carries a high mortality. It has been shown that hemofiltration improves cardiac function during and after cardiopulmonary bypass by removal of myocardial depressant substances and/or cytokines. The aim of this study was to evaluate the safety and efficiency of HV-CVVH with a highly permeable filter, started early in patients with acute renal failure following heart surgery. 36 cardio-surgical patients (mean age 67) were included. Most of the patients were suffering from acute renal failure as a consequence of a low-output syndrome after cardiac surgery. We used cellulose triacetate membrane, surface area 1.9 m2, cutoff 50.000 D. An ultrafiltrate flow was 50-80 ml/min. Parameters of renal function, changes in inotropic support, arterial blood pressure, pulmonary gas exchange (PO2/FiO2 ratio) before and after hemofiltration treatment, were retrospectively analyzed. Values of serum creatinine levels, serum urea levels and doses of dopamine, noradrenaline, enoximone, as well as, values of positive end expiratory pressure and the PaO2/FiO2 ratio before the first, and after or at the end of the last run of HV-CVVH, were compared by the paired t-test. We observed a low incidence of complications related to hemofiltration. Hemofiltration normalized serum urea and creatinine levels within 24 hours. The need for inotropic support after HV-CVVH was lower than before. The PaO2/FiO2 ratio was significantly higher after HV-CVVH than before. In the 29 patients in whom renal function was recovered, the median time of recovery was 96 hours and in 86% of these patients the function recovered within 10 days. Hospital mortality was 30.3%. High volume continuous venovenous hemofiltration is a safe and effective treatment in post cardiac surgery patients. HV-CVVH seems to improve the cardiac and respiratory functions.
Keywords: Hemofiltration, Multiple Organ Failure, renal failure, cardiac surgery
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952